Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]-Uproleselan in Healthy Subjects
NCT03606447Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of uproleselan in acute myeloid leukemia (AML), sponsored by GlycoMimetics. Primary endpoints: Mass Balance Recovery up to 8 days, Time to Maximum Concentration up to 8 days and 6 more. Started Aug 2018; status: completed.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03606447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606447.